Senior scientists from the UK’s two big pharma companies GlaxoSmithKline and AstraZeneca say only a rapid and significant increase in government R&D spending will boost the UK life
Europe’s drugs regulator has issued a temporary staffing contract worth up to £32 million, in order to ensure it has enough hands on deck while it relocates from London as part of Brexit.
